Ashwani Verma
Stock Analyst at UBS
(3.93)
# 773
Out of 5,182 analysts
111
Total ratings
55.13%
Success rate
9.9%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPRX Royalty Pharma | Maintains: Buy | $51 → $57 | $49.54 | +15.06% | 4 | Apr 21, 2026 | |
| AMRX Amneal Pharmaceuticals | Initiates: Buy | $19 | $12.74 | +49.20% | 1 | Apr 17, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $251 → $259 | $185.00 | +40.00% | 8 | Apr 10, 2026 | |
| INCY Incyte | Maintains: Neutral | $104 → $94 | $97.74 | -3.83% | 3 | Mar 25, 2026 | |
| ALVO Alvotech | Maintains: Buy | $10 → $6 | $3.52 | +70.45% | 2 | Mar 24, 2026 | |
| CYTK Cytokinetics | Maintains: Neutral | $61 → $69 | $60.69 | +13.69% | 6 | Mar 6, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $655 → $705 | $569.11 | +23.88% | 12 | Mar 5, 2026 | |
| HRMY Harmony Biosciences Holdings | Downgrades: Neutral | $43 → $46 | $31.16 | +47.63% | 4 | Feb 11, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $178 | $128.12 | +38.93% | 11 | Jan 23, 2026 | |
| INSM Insmed | Maintains: Buy | $223 → $215 | $134.94 | +59.33% | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $40 | $22.67 | +76.44% | 9 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $95 | $46.62 | +103.78% | 1 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $48 | $23.56 | +103.74% | 4 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $26 → $11 | $9.61 | +14.46% | 5 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $163 → $188 | $203.98 | -7.83% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $195 → $220 | $197.69 | +11.29% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $40 | $44.93 | -10.97% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $31.62 | -17.77% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $26.99 | -33.31% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $34.14 | +23.02% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.77 | -40.68% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $115.07 | -0.93% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $303.97 | -97.70% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $14.82 | -19.03% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.87 | +1,628.11% | 1 | Oct 11, 2022 |
Royalty Pharma
Apr 21, 2026
Maintains: Buy
Price Target: $51 → $57
Current: $49.54
Upside: +15.06%
Amneal Pharmaceuticals
Apr 17, 2026
Initiates: Buy
Price Target: $19
Current: $12.74
Upside: +49.20%
Axsome Therapeutics
Apr 10, 2026
Maintains: Buy
Price Target: $251 → $259
Current: $185.00
Upside: +40.00%
Incyte
Mar 25, 2026
Maintains: Neutral
Price Target: $104 → $94
Current: $97.74
Upside: -3.83%
Alvotech
Mar 24, 2026
Maintains: Buy
Price Target: $10 → $6
Current: $3.52
Upside: +70.45%
Cytokinetics
Mar 6, 2026
Maintains: Neutral
Price Target: $61 → $69
Current: $60.69
Upside: +13.69%
United Therapeutics
Mar 5, 2026
Maintains: Buy
Price Target: $655 → $705
Current: $569.11
Upside: +23.88%
Harmony Biosciences Holdings
Feb 11, 2026
Downgrades: Neutral
Price Target: $43 → $46
Current: $31.16
Upside: +47.63%
Neurocrine Biosciences
Jan 23, 2026
Maintains: Buy
Price Target: $188 → $178
Current: $128.12
Upside: +38.93%
Insmed
Jan 6, 2026
Maintains: Buy
Price Target: $223 → $215
Current: $134.94
Upside: +59.33%
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $22.67
Upside: +76.44%
Dec 16, 2025
Initiates: Neutral
Price Target: $95
Current: $46.62
Upside: +103.78%
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $23.56
Upside: +103.74%
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $9.61
Upside: +14.46%
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $203.98
Upside: -7.83%
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $197.69
Upside: +11.29%
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $44.93
Upside: -10.97%
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $31.62
Upside: -17.77%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $26.99
Upside: -33.31%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $34.14
Upside: +23.02%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.77
Upside: -40.68%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $115.07
Upside: -0.93%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $303.97
Upside: -97.70%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $14.82
Upside: -19.03%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.87
Upside: +1,628.11%